CEL-SCI remains focused on advancing Multikine, a Phase 3 immunotherapy for head and neck cancers, targeting a patient segment underserved by current checkpoint inhibitors. The company’s May 2026 quarterly report underscores significant financing challenges, with an estimated $30-$35 million needed for a confirmatory registration study critical to regulatory approval pathways. Despite promising survival data and strategic partnerships in the Middle East, CEL-SCI operates under substantial doubt about its going concern status due to ongoing losses and limited liquidity. Long-term growth hinges on successful trial completion, regulatory clearances, and capital availability.